このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

A Randomized Controlled Multicenter Trial of Exercise Training in Pulmonary Hypertension in European Countries (EU-TRAIN-01)

2019年12月17日 更新者:Prof. Dr. med. Ekkehard Gruenig、Heidelberg University

Implementation and Effect of Exercise and Respiratory Training on 6-minute Walking Distance in Patients With Severe Chronic Pulmonary Hypertension: a Randomized Controlled Multicenter Trial in European Countries

Chronic pulmonary hypertension (PH) is associated with impaired exercise capacity, quality of life and right ventricular function. The disease is characterized by an increase of pulmonary vascular resistance and pulmonary arterial pressure, leading to right heart insufficiency.

Despite optimized combination-medical therapy most patients remain symptomatic, have reduced exercise capacity, quality of life and reduced survival rates, with an annual mortality rate of approximately 5 -15 % or even higher.

Previous training studies have suggested that exercise training as add-on to medical treatment is highly effective improving exercise capacity, quality of life and symptoms.

The current guidelines recommend exercise training only in specialized centres including both PH and rehabilitation specialists who are experienced in exercise training of severely compromised patients.

A specialized PH-training program has been performed in Heidelberg since 2003 including >1200 patients with various forms of chronic PH. The exercise training program is performed in a special setting with an in-hospital start of the rehabilitation program. It is characterized by a low-dose closely supervised exercise training in small groups with additional psychological support and mental training.

This training program for patients with PH will be implemented in European centers to add exercise training to the existing PH therapies. The effect of the training on physical exercise capacity will be assessed by 6-minute walking distance (6-MWD). Further clinical parameters will be assessed to evaluate the effect on exercise capacity, quality of life and symptoms.

The aim of this study is to guide European PH-centers to become specialized centers for training in PH.

126 patients will be included, who either receive exercise training or continue their daily sedentary life style (1:1 randomization) for 15 weeks.

As inpatient settings are not available in all healthcare systems the training program will be adapted from the specific training program for PH patients developed in Heidelberg to a procedure, which is feasible in the local participating centres. Another objective of this study is to assess if the particular adopted training program specified for each participating centre and country is still safe and effective.

調査の概要

状態

完了

詳細な説明

Pulmonary hypertension (PH) is defined as a mean pulmonary arterial pressure ≥25 mmHg. PH is often diagnosed at an advanced stage (WHO functional class III-IV) with a massive increase of the mean pulmonary arterial pressure. A crucial parameter determining the symptoms and prognosis of the patients is the cardiac reserve. This parameter is defined by the pulmonary vascular resistance and the right ventricular adaptation. Severe PH is characterized by a decreased cardiac output at rest, an increased afterload and consecutive cor pulmonale.

Within the last years there has been a huge progress in the scientific fields of genetics, pathogenesis, pathophysiology and therapy of PH. This has also been documented in the PH world conferences. New disease-targeted medication has been developed such as endothelin receptor antagonists (bosentan, ambrisentan, sitaxentan, macitentan), prostacyclin derivates (inhaled and intravenous iloprost, epoprostenol, treprostinil), phosphodiesterase-5-inhibitors (sildenafil, tadalafil) and the soluble guanylate cyclase inhibitor riociguat. Despite these advances in treatment, the disease may not be treated causally or even be cured. In most cases however, disease progression may be slowed down. The use of PH-targeted treatment and supporting therapies such as anticoagulation and diuretics improve the symptoms and impede the progression of the disease. Nevertheless, the prognosis of the patients remains impaired. The first randomized controlled study investigating the effect of exercise training in PH showed a significant improvement of exercise capacity and quality of life. Further uncontrolled trials using a low-dose exercise and respiratory therapy in different etiologies of PH showed an improvement in exercise capacity, quality of life, muscle function and further prognostic parameters. A recent randomized controlled study could support these findings. Studies also showed an improvement in muscle capillarization of the quadriceps muscle.

The training program consists of interval ergometer training, respiratory therapy, muscle training and mental gait training. The interval ergometer training allows performing aerobic exercise training with a low cardio-circulatory stress. In patients with left heart insufficiency, this training has been successfully implemented. Respiratory therapy has been established in the rehabilitation of patients with lung disease within the last years. The different techniques aim to improve ventilation, strengthen the respiratory muscles, mobilize the thorax and enhance secretolysis. The training program also contains mental (gait) training. This training was adapted from mental imagery techniques used by sport psychologists in professional athletes. Mental imagery techniques have shown to improve physical and cognitive functions.

Due to the beneficial results, exercise training and rehabilitation has received a 1A recommendation at the PH world symposium in Nice in 2013. This decision was mainly based on three randomized controlled trials that investigated a limited number of patients. To unequivocally demonstrate safety and positive effects of exercise training in different settings large multicenter RCTs are essential. An exercise program has not yet been implemented in most European countries, partly due to limited access to rehabilitation programs and institutions.

The aim of this large, multicenter, prospective, randomized controlled trial is to investigate the effect of exercise training and rehabilitation on physical exercise capacity across different European countries. Physical exercise capacity will be measured by exercise induced change of 6-minute walking distance (6-MWD) compared to baseline and the control group without training. As inpatient settings are not available in all healthcare systems the training program will be adapted from the specific training program for PH patients developed in Heidelberg in a system, which is feasible for the local participating centres. Another objective of this study is to assess if the adopted training program specified for each participating centre and country is still safe and effective.

研究の種類

介入

入学 (実際)

129

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

      • Heidelberg、ドイツ、69126
        • Centre for pulmonary hypertension of the Thoraxclinic at the University Hospital Heidelberg

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  • Female and male patients of any ethnic origin ≥ 18 years
  • WHO functional class II-IV
  • PH diagnosed by right heart catheter showing:

    • Baseline mean pulmonary arterial pressure (mPAP) ≥ 25 mmHg
    • Baseline pulmonary vascular resistance (PVR) ≥ 240 dyn x s x cm-5
    • Baseline pulmonary capillary wedge pressure (PCWP) ≤ 15 mm Hg
  • Patients receiving optimized conventional PH therapy including intensified treatment with diuretics and who have been stable for 2 months before entering the study
  • Except for diuretics, medical treatment should not be expected to change during the entire 15-week study period
  • Negative pregnancy test (β-HCG) at the start of the trial and appropriate contraception throughout the study for women with child-bearing potential
  • Able to understand and willing to sign the Informed Consent Form

Exclusion Criteria:

  • PH of any cause other than permitted in the entry criteria, e.g. concomitantly to portal hypertension, complex congenital heart disease, reversed shunt, HIV infection, suspected pulmonary veno-occlusive disease based on pulmonary edema during a previous vasoreactivity test or on abnormal findings compatible with that diagnosis (septal lines or pulmonary edema at high resolution computer tomography), congenital or acquired valvular defects with clinically relevant myocardial function disorders not related to pulmonary hypertension or unclear diagnosis
  • Pregnancy
  • Patients with signs of right heart decompensation
  • Walking disability
  • Acute infection
  • Pyrexia
  • Any change in disease-targeted therapy within the last 2 months
  • Any subject who is scheduled to receive an investigational drug during the course of this study
  • Severe lung disease: FEV1/FVC <0.5 and total lung capacity < 70% of the normal value
  • Active liver disease, porphyria or elevations of serum transaminases >3 x ULN (upper limit of normal) or bilirubin > 1.5 x ULN
  • Hemoglobin concentration of less than 75 % of the lower limit of normal
  • Systolic blood pressure < 85 mmHg
  • Active myocarditis, instable angina pectoris, exercise induced ventricular arrhythmias, decompensated heart failure, hypertrophic obstructive cardiomyopathy, highly impaired left ventricular function
  • History or suspicion of inability to cooperate adequately. will be excluded from the study.

Additional exclusion criteria for MRI (optional)

  • Acute psychosis or other states of mind, which seem to impair patient's ability to comprehend instructions
  • Patients with metal cardiac valves or other metal implants, incorporated ferromagnetic materials or MRI-incompatible active medicinal products
  • Claustrophobia

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:診断
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
介入なし:Control group
Patients in this group continue their sedentary life-style throughout the study period. Patients will be advised to perform no specific exercise training during the trial. After 15 weeks, the patients are offered to take part in the training program as well.
実験的:Training group

Standard rehabilitation therapy includes dietary measures, massages and relaxation techniques. Additionally, patients perform exercise and respiratory therapy and mental gait training.

Patients will be informed about group allocation.

The rehabilitation program comprises interval ergometer training, dumbbell training, respiratory therapy, mental training and guided walks for 5-7 times/week.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
6 MWD
時間枠:15 weeks
Change in 6-MWD between baseline and 15 weeks in the training vs. the control Group; meters
15 weeks

二次結果の測定

結果測定
メジャーの説明
時間枠
Change in WHO functional class in training vs. control group
時間枠:15 weeks
WHO functional class
15 weeks
Change in Quality of life in training vs. control group
時間枠:15 weeks
Quality of life (SF-36)
15 weeks
Change in Borg scale 6-MWD training vs. control group
時間枠:15 weeks
Borg scale 6-MWD
15 weeks
Change in tricuspid annular plane systolic excursion
時間枠:15 weeks
Echocardiographic parameter training vs. control Group; mm
15 weeks
Change in tissue Doppler imaging
時間枠:15 weeks
Echocardiographic Parameter training vs. control group
15 weeks
Change in left ventricular pump function
時間枠:15 weeks
Echocardiographic Parameter training vs. control Group; qualitative
15 weeks
Change in right ventricular pump function
時間枠:15 weeks
Echocardiographic Parameter training vs. control Group; qualitative
15 weeks
Change in thickness of interventricular septum
時間枠:15 weeks
Echocardiographic Parameter training vs. control Group; mm
15 weeks
Change insize of inferior vena cava
時間枠:15 weeks
Echocardiographic Parameter training vs. control Group; mm
15 weeks
Change in systolic pulmonary arterial pressure
時間枠:15 weeks
Echocardiographic Parameter training vs. control Group; mmHg
15 weeks
Change in left ventricular eccentricity index
時間枠:15 weeks
Echocardiographic Parameter training vs. control group
15 weeks
Change in Tei index
時間枠:15 weeks
Echocardiographic Parameter training vs. control group
15 weeks
Change in right ventricular area
時間枠:15 weeks
Echocardiographic Parameter training vs. control group
15 weeks
Change in right atrial area
時間枠:15 weeks
Echocardiographic Parameter training vs. control Group; square cm
15 weeks
Change in workload
時間枠:15 weeks
Cardiopulmonary exercise testing (spiroergometry) training vs. control Group; Watts
15 weeks
Change in heart rate
時間枠:15 weeks
Cardiopulmonary exercise testing (spiroergometry) training vs. control Group; bpm
15 weeks
Change in ventilation
時間枠:15 weeks
Cardiopulmonary exercise testing (spiroergometry) training vs. control Group; L/min
15 weeks
Change in carbon dioxide output
時間枠:15 weeks
Cardiopulmonary exercise testing (spiroergometry) training vs. control Group
15 weeks
Change in spiroergometry parameters in training vs. control group
時間枠:15 weeks
Cardiopulmonary exercise testing (spiroergometry): VO2 at anaerobic threshold determined by V-slope method
15 weeks
Change in VCO2 at anaerobic threshold
時間枠:15 weeks
Cardiopulmonary exercise testing (spiroergometry): determined by V-slope method
15 weeks
Change in oxygen uptake
時間枠:15 weeks
Cardiopulmonary exercise testing (spiroergometry); L/min/kg
15 weeks
Change in diffusion-limited carbon monoxide (DLCO)
時間枠:15 weeks
Lung function; Diffusion capacity
15 weeks
Change in alveolar volume (VA)
時間枠:15 weeks
Lung function
15 weeks
Change in residual volume (RV)
時間枠:15 weeks
Lung function
15 weeks
Change in total lung volume (TLC)
時間枠:15 weeks
Lung function
15 weeks
Change in forced expiratory flow
時間枠:15 weeks
Lung function
15 weeks
Change in peak expiratory flow rate
時間枠:15 weeks
Lung function
15 weeks
Change in forced expiratory volume in one second (FEV1)
時間枠:15 weeks
Lung function; total and in percentage
15 weeks
Change in forced vital capacity (FVC)
時間枠:15 weeks
Lung function
15 weeks
Change in NTproBNP
時間枠:15 weeks
Laboratory marker for the impairment of the right heart
15 weeks
Change in interleukins
時間枠:15 weeks
Laboratory marker for the impairment of the right heart
15 weeks
Change in inflammatory markers
時間枠:15 weeks
Laboratory marker for the impairment of the right heart
15 weeks
Change in carbon dioxide partial pressure
時間枠:15 weeks
Blood gas Analysis
15 weeks
Change in oxygen saturation of the blood (SaO2)
時間枠:15 weeks
Blood gas analysis
15 weeks
Change in additional oxygen supplementation (yes/no and quantity)
時間枠:15 weeks
Blood gas analysis
15 weeks
Change in oxygen partial pressure
時間枠:15 weeks
Blood gas analysis
15 weeks
Change in oxygen saturation
時間枠:15 weeks
Safety Parameter; L/min
15 weeks
Assessment of clinical laboratory Investigation alerts (values out of range)
時間枠:15 weeks
Safety parameter
15 weeks
Assessment of adverse Events
時間枠:15 weeks
Safety Parameter; unrelated and related to procedure
15 weeks
Assessment of serious adverse events
時間枠:15 weeks
Safety parameter
15 weeks
frequency of hospitalizations
時間枠:15 weeks
Safety parameter
15 weeks
length of hospitalizations
時間枠:15 weeks
Safety parameter
15 weeks
Change in resting heart rate
時間枠:15 weeks
Safety parameter
15 weeks
Change in blood pressure
時間枠:15 weeks
Safety parameter
15 weeks
frequency of pathological findings in long-term ECG
時間枠:15 weeks
Safety parameter
15 weeks
Qualitative Review of electrocardiogram (ECG)
時間枠:15 weeks
Safety Parameter; pathological findings
15 weeks
Assessment of survival
時間枠:1 year
Training and control Group; transplant-free and Overall survival
1 year
Change of the right ventricular size
時間枠:15 weeks
Optional: Changes in MRI parameters
15 weeks
Change of the right ventricular pump function
時間枠:15 weeks
Optional: Changes in MRI parameters
15 weeks
Change of the left ventricular size
時間枠:15 weeks
Optional: Changes in MRI parameters
15 weeks
Change of the left ventricular pump function
時間枠:15 weeks
Optional: Changes in MRI parameters
15 weeks
Change in microRNA expression
時間枠:15 weeks
Optional: Epigenetic changes
15 weeks
Change in DNA-methylation
時間枠:15 weeks
Optional: Epigenetic changes
15 weeks
Assessment of relationship of DNA mutations and disease progression
時間枠:15 weeks
Optional: Investigation of DNA mutations relationship to disease progression
15 weeks
Assessment of relationship of DNA mutations and training effects
時間枠:15 weeks
Optional: Investigation of DNA mutations
15 weeks

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • 主任研究者:Ekkehard Grünig, MD、Centre for pulmonary hypertension of the Thoraxclinic at the University Hospital Heidelberg

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

一般刊行物

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2016年2月1日

一次修了 (実際)

2018年12月1日

研究の完了 (実際)

2019年12月1日

試験登録日

最初に提出

2017年7月27日

QC基準を満たした最初の提出物

2017年11月13日

最初の投稿 (実際)

2017年11月17日

学習記録の更新

投稿された最後の更新 (実際)

2019年12月19日

QC基準を満たした最後の更新が送信されました

2019年12月17日

最終確認日

2019年12月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • EU-TRAIN-01

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する